w*********7
发帖数: 2883 | 1 【 以下文字转载自 JQCLUB 俱乐部 】
发信人: winnie91107 (爱的承诺), 信区: JQCLUB
标 题: ISIS
发信站: BBS 未名空间站 (Fri Aug 5 13:32:08 2011, 美东)
Isis Reports Financial Results and Highlights for Second Quarter 2011
21 hours 30 minutes ago - PR Newswire via Comtex
PR Newswire
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial
results for the quarter ended June 30, 2011. The Company finished the second
quarter of 2011 with a pro forma net operating loss (NOL) of $11.6 million
and $24.9 million for the thr... 阅读全帖 |
|
j*****7
发帖数: 4348 | 2 "Second, we’ve mentioned on several calls that our annual meeting will be held this year on June 2. During our annual meeting, we’ll be doing something a little different. The scientific session of our annual meeting not only be comprised of scientific poster session with a lead scientist, but we’ll also host mipomersen panel comprised of three expert physicians, knowledgeable in cardiovascular medicine herpetology, Dr. William Cromwell, Dr. Willis Maddrey and Dr. Joseph Whitson.
These senior ph... 阅读全帖 |
|
y*****l
发帖数: 5997 | 3 http://www.thestreet.com/story/11016605/1/biotech-calendars-201
By Adam Feuerstein 02/22/11 - 07:36 AM ES
Stock quotes in this article:HGSI, OPTR, XNPT, SPPI, DRRX, PATH
BOSTON (TheStreet) -- I've updated the 2011 FDA drug approval calendar.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regul... 阅读全帖 |
|
O**I
发帖数: 776 | 4 【 以下文字转载自 pennystock 俱乐部 】
发信人: OSCI (TX), 信区: pennystock
标 题: FDA Drug Approvals in 2011
发信站: BBS 未名空间站 (Sat Jan 8 17:29:50 2011, 美东)
http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
... 阅读全帖 |
|
O**I
发帖数: 776 | 5 http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
Orexigen Therapeutics Inc.| OREX
DOWN
Dendreon Corporation| DNDN
InterMune Inc.| ITMN
For easy reference, I've organized this regulatory ... 阅读全帖 |
|
O**I
发帖数: 776 | 6 http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
Orexigen Therapeutics Inc.| OREX
DOWN
Dendreon Corporation| DNDN
InterMune Inc.| ITMN
For easy reference, I've organized this regulatory ... 阅读全帖 |
|
w*******0
发帖数: 13 | 7 BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regulatory milestones in 2011 based on
expected but not yet completed drug approval filings.
In all, this calendar ... 阅读全帖 |
|
w*******0
发帖数: 13 | 8 BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regulatory milestones in 2011 based on
expected but not yet completed drug approval filings.
In all, this calendar ... 阅读全帖 |
|
g****e
发帖数: 1426 | 9 See below presentation scripts from coo &cfo about Isis. Its pipeline is
amazing, more than 25 drugs!! Actually based on this reading, I bought it
yesterday since all negative news on kynamro/mipomersen already mentioned
there.
http://m.seekingalpha.com/article/876781
AEGR essentially has only one drug, if AEGR is valued more than half billion
, then there is no double that Isis could fill the gap and go much much
higher!! It will move over 13 next week, give it some time to fly! |
|
j*****7
发帖数: 4348 | 10 1) EXEL: ASCO上会有PE和记者招待会, poster大概下礼拜出来, 重点是XL-184. 照着公司管理层的说法, 今年肯定lock大于一个的partnership deal
2) ISIS: 六月二号公司召开年度大会, 届时将有三名专家到会, 会涉及mipomersen的
efficacy和SAFETY.
3) PLX: 年底前FDA应该会对taliglucerase alfa作出决定.
BTW, 发现了一个挺好的biotech company, Galapagos NV, 在比利时, 我想在IB下单,
可是不知道怎么会事, 单一下就被cancel了. |
|
